Phaseline

Targets › HER3

HER3 (Receptor tyrosine-protein kinase erbB-3): drug programs, companies and trials

4 programs from 4 companies in 22 trials: 15 Phase 2, 6 Phase 1, 1 Phase 3; Oncology; next expected readout Nov 2026.

Tyrosine kinase receptor that, despite substitutions of key catalytic residues in the kinase domain, retains residual catalytic activity enabling autophosphorylation. Functions primarily as a heterodimer, preferentially partnering with ERBB2/HER2, which phosphorylates ERBB3 on specific tyrosine residues and provides the kinase activity required for downstream signaling. (UniProt, P21860)

Open in Phaseline: the race on HER3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sichuan Baili PharmaceuticalSI-B001
EGFR/HER3 bispecific antibody
EGFR, HER3Phase 3Non-small Cell Lung Adenocarcinoma; Non-small Cell Lung Cancer; Esophageal Squamous Cell Carcinomas; Head and Neck Squamous Cell Carcinoma …Nov 2026
Shanghai Junshi Bioscience Co., Ltd.JS212 for Injection
Bispecific antibody-drug conjugate targeting EGFR and HER3 with topoisomerase I inhibitor
EGFR, HER3Phase 2Advanced Esophageal Squamous Cell Carcinoma; Advanced Malignant Solid Tumors; Advanced Lung Cancer; Metastatic Colorectal Cancer …Jun 2027
Hangzhou Zhongmei Huadong PharmaceuticalHDM2024
Antibody-drug conjugate targeting EGFR and HER3
EGFR, HER3Phase 1Advanced Solid TumorsApr 2027
BioNTech SEanti-HER3 antibody conjugated to topoisomerase I inhibitor
anti-HER3 antibody-drug conjugate with topoisomerase I inhibitor
HER3Phase 1Non-Small Cell Lung CancerFeb 2030

Conditions

Head and Neck Squamous Cell Carcinoma (3) Non-small Cell Lung Cancer (2) Triple-negative Breast Cancer (2) Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations (2) Non-small Cell Lung Adenocarcinoma (1) Esophageal Squamous Cell Carcinomas (1) Non Small Cell Lung Cancer (1) Locally Advanced or Metastatic Epithelial Tumor (1) Squamous Cell Carcinoma of Head and Neck (1) Advanced Solid Tumors (1) Advanced Esophageal Squamous Cell Carcinoma (1) Advanced Malignant Solid Tumors (1)

Modalities

small molecule (3), mixed (1)

Companies

Sichuan Baili Pharmaceutical (1) Hangzhou Zhongmei Huadong Pharmaceutical (1) Shanghai Junshi Bioscience Co., Ltd. (1) BioNTech SE (1)

Related targets

EGFR (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.